ReviewWorld journal of gastroenterology2016
How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia?
Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Comprehensive evaluation of the prevalent insulin resistance indices for pan-cancer incidence and mortality prediction.Tropical medicine and health · 2025Article
- Article
- A Scoring Method to Prioritize Fecal Occult Blood Testing as a First Step in Colorectal Cancer Screening in Resource-Limited Settings.Diagnostics (Basel, Switzerland) · 2023Article
- Risk Factors of Young-Onset Colorectal Cancer: Analysis of a Large Population-Based Registry.Canadian journal of gastroenterology & hepatology · 2022Article
- Pathophysiological Characteristics Linking Type 2 Diabetes Mellitus and Colorectal Neoplasia.Physiological research · 2021Review
- Association between cardiovascular risk factors and colorectal cancer: A systematic review and meta-analysis of prospective cohort studies.EClinicalMedicine · 2021Article
- Elevated serum triglyceride predicts recurrence of colorectal polyps in patients with advanced adenomas.Lipids in health and disease · 2020Article
- Long-term Risk of Malignant Neoplastic Disorders in Type 2 Diabetes Mellitus Patients with Metabolic Syndrome.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
- Cardiovascular risk factors among cancer patients qualified for systemic treatment. Analysis of a cardiovascular disease-free cohort from the Polish multicentre study ONCOECHO.Archives of medical science : AMS · 2020Article
- Elevated serum triglyceride and low-density lipoprotein cholesterol promotes the formation of colorectal polyps.BMC gastroenterology · 2019Article
- Association of gout and colorectal cancer in Taiwan: a nationwide population-based cohort study.BMJ open · 2019Article
- SREBP1 promotes the invasion of colorectal cancer accompanied upregulation of MMP7 expression and NF-κB pathway activation.BMC cancer · 2019Article
- Association of visceral adiposity and insulin resistance with colorectal adenoma and colorectal cancer.Intestinal research · 2019Article
- Influence of Obesity and Metabolic Abnormalities on the Risk of Developing Colorectal Neoplasia.Digestive diseases and sciences · 2018Article
- Specific features of colorectal cancer in patients with metabolic syndrome: a matched case-control analysis of 772 patients.Langenbeck's archives of surgery · 2018Article
- Association between Nutrient Intake and Metabolic Syndrome in Patients with Colorectal Cancer.Clinical nutrition research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence and prevalence of metabolic syndrome (MS) and colorectal cancer (CRC) has been rising in developed countries. The association between these two diseases has been widely studied and reported. Less evidence is available about the relationship between MS and CRC precancerous lesions (adenomatous polyps, adenomas). The aim of this paper is to present an overview of our scientific understanding of that topic and its implication in clinical practice. One of the principal goals of current CRC secondary prevention efforts is to detect and remove the precancerous lesions in individuals with an average CRC risk to prevent the development of invasive cancer. MS is not currently considered a high-risk CRC factor and is therefore not included in the guidelines of organized screening programs. However, in light of growing scientific evidence, the approach to patients with MS should be changed. Metabolic risk factors for the development of adenomas and cancers are the same - obesity, impaired glucose tolerance, dyslipidemia, hypertension, cardiovascular diseases and diabetes mellitus type 2. Therefore, the key issue in the near future is the development of a simple scoring system, easy to use in clinical practice, which would identify individuals with high metabolic risk of colorectal neoplasia and would be used for individual CRC secondary prevention strategies. Currently, such scoring systems have been published based on Asian (Asia-Pacific Colorectal Screening Score; APCS) and Polish populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.